CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,100,727 | -15.4% | 68,313 | +4.7% | 0.06% | -11.9% |
| Q2 2023 | $3,663,135 | +32.6% | 65,250 | +6.9% | 0.07% | +21.8% |
| Q1 2023 | $2,761,518 | +37.9% | 61,055 | +24.0% | 0.06% | +27.9% |
| Q4 2022 | $2,002,013 | -42.4% | 49,250 | -7.4% | 0.04% | -44.9% |
| Q3 2022 | $3,476,000 | +31.1% | 53,189 | +21.9% | 0.08% | +110.8% |
| Q2 2022 | $2,651,000 | +16.7% | 43,625 | +20.6% | 0.04% | +48.0% |
| Q1 2022 | $2,271,000 | -41.8% | 36,181 | -29.7% | 0.02% | -30.6% |
| Q4 2021 | $3,899,000 | -29.1% | 51,445 | +4.7% | 0.04% | -32.1% |
| Q3 2021 | $5,502,000 | -36.2% | 49,158 | -7.7% | 0.05% | -31.2% |
| Q2 2021 | $8,624,000 | +0.1% | 53,272 | -24.7% | 0.08% | -3.8% |
| Q1 2021 | $8,619,000 | -52.6% | 70,735 | -40.4% | 0.08% | -52.4% |
| Q4 2020 | $18,166,000 | +94.3% | 118,647 | +6.1% | 0.17% | +63.1% |
| Q3 2020 | $9,349,000 | – | 111,780 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |